

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/50, 31/44	A1	(11) International Publication Number: WO 98/19668 (43) International Publication Date: 14 May 1998 (14.05.98)
(21) International Application Number: PCT/US97/20851 (22) International Filing Date: 5 November 1997 (05.11.97) (30) Priority Data: 08/740,981 6 November 1996 (06.11.96) US (71) Applicant (for all designated States except US): SHAR-MATEK, INC. [US/US]; 12 Walnut Drive, Long Valley, NJ 07853 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): SHARMA, Vinay, K. [US/US]; 12 Walnut Drive, Long Valley, NJ 07853 (US). (74) Agent: VIKSINS, Ann, S.; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).		(81) Designated States: AU, ID, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: **DELAYED DELIVERY SYSTEM FOR ACID-SENSITIVE DRUGS**



(57) Abstract

The present invention relates to a delayed release drug delivery system containing omeprazole capable of site-specific delivery and pulsatile (bolus) kinetics for once-a-day dosage comprised of an alkaline core structure sequentially layered with suspensions of omeprazole; a separation barrier; and an enteric barrier. The separation barrier is coated with a pH-dependent enteric membrane, which is relatively insoluble in gastric fluid but rapidly to immediately soluble in intestinal fluid, whereby the drug is released in a pulsatile manner in the proximal segment of the gastrointestinal tract.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DELAYED DELIVERY SYSTEM FOR ACID-SENSITIVE DRUGS

5

Background of the Invention

(1) Field of the Invention

The present invention relates to a drug delivery system and, more particularly, to a delayed release drug delivery system for drugs or biologically active materials (e.g., vitamins, vaccines, antibiotics, antifungal agents, muscle relaxers, mood altering drugs, and the like), and especially omeprazole. The system is capable of site-specific delivery and pulsatile (bolus) kinetics.

(2) Description of Prior Art

Omeprazole provides a powerful inhibitory action against secretion of gastric juices and can be used for treatment of gastric and duodenal ulcers. (*Lancet*, Nov. 27, 1982, pp. 1223-24). However, omeprazole is susceptible to degradation in acidic, acid reactive and neutral media, i.e., the half-life of degradation at pH 4 is less than six minutes, whereas at pH 7 it is about 14 hours. Human pharmacological studies have found that the rate of release of omeprazole can influence the total extent of absorption of the drug to the general circulation. A fully bioavailable dosage form should release the drug rapidly in the proximal part of the gastrointestinal tract.

U.S. Patent No. 4,786,505 discloses that the stability of conventional formulae of omeprazole is not satisfactory. The reference describes a dosage form including a core region containing omeprazole mixed with alkaline compounds or an alkaline salt of omeprazole mixed with an alkaline compound, or an alkaline omeprazole salt alone coated with one or more layers. The layer/layers which is/are comprised of an alkaline material separates/separate the core material from the outer layer, which is an enteric coating disposed on a subcoating. The final enteric-coated dosage form is treated to reduce water content in order to obtain stability of the drug during long-term storage.

U.S. Patent No. 4,853,230 describes a pharmaceutical preparation comprising an alkaline-reacting core containing an acid-labile pharmaceutical

substance and a pH-buffering alkaline-reacting compound which provides a pH of 7-12 to the micro-environment of the acid labile compound. A subcoating layer is composed of tablet excipients, film forming compounds, and alkaline buffering compounds. Finally, an enteric coating layer surrounds the subcoating layer, wherein the subcoating layer isolates the alkaline-reacting core from the enteric coating layer such that the stability of the product is enhanced.

Omeprazole, along with many other drugs (e.g., Captopril) or biologically active materials (e.g., beta-lactams), vitamins, vaccines, antibiotics, antifungal agents, muscle relaxers, mood altering drugs, and the like can be acid sensitive. That is, their active properties can decrease significantly in the presence of acids, usually by deterioration of the drug or chemical reaction with the drug, altering its composition. The use of enteric layers, which generally comprise layers with carboxyl groups or other acid groups, can adversely affect the stability of the acid sensitive ingredients, since the acid groups on the polymers or other ingredients used in the enteric coating can directly contribute to the acid sensitizing capability of the environment of the pellets during storage.

SUMMARY OF THE INVENTION

The present invention provides a delayed release drug delivery system containing an acid sensitive drug which is stable at pH levels above 9.0, or biologically active material which is acid sensitive yet stable at pH levels above 9.0, such as omeprazole, for once-a-day dosage. The present invention provides a dose of an acid sensitive drug which is stable at pH levels above 9.0, or biologically active material which is acid sensitive yet stable at pH levels above 9.0, such as omeprazole comprising an alkaline core structure of high cohesiveness and integrity, capable of withstanding the pressure of attrition during a layering operation. One aspect of the present invention is to take advantage of the alkaline core structure, for optimization of release and stability of acid sensitive drugs such as with omeprazole release. Another aspect of the present invention is to provide a delayed release dosage form of an acid sensitive drug, such as omeprazole which is resistant to dissolution in acid media. Another aspect of the invention is to provide at least one sub-separation layer in

the pellets adjacent to a layer containing the active acid sensitive material, the sub-separation layer comprising a water soluble/water dispersible polymer and a pharmaceutically acceptable water soluble buffer which can provide a pH of at least 9.0 (depending upon the stabilization needs of the individual compounds), preferably at least 9.5, more preferably at least 10.0, and most preferably (in the case of omeprazole), at least 10.5 or at least 11.0 (up to 12, for example). The use of the high pH buffer materials assures that even in the presence of moisture which could cause migration of acid within the pellets, the high pH buffer would reduce any effect that migratory acid could have on the system.

A further aspect of the present invention is to provide a delayed release dosage form of an acid sensitive drug such as omeprazole which dissolves rapidly in neutral-to-alkaline media. A still further aspect of the present invention is to provide a delayed release dosage form of omeprazole having good stability during long term storage.

The present invention includes both multicompartment pellets and monocompartment pellets for the release of acid sensitive drugs or biologically active materials. The monocompartment pellets, for example, might include a substrate (e.g., nonpareil), a subseparation layer (e.g., a water-soluble or water dispersible binder or polymer (especially cellulose based polymers), such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose incorporates and mixtures thereof (including with other types of water soluble or water insoluble polymers and binders, which two layers define an alkaline core structure) and a layer of deposited omeprazole, especially as from suspensions of omeprazole or micronized omeprazole, followed by a semipermeable moisture barrier layer, and finally with an enteric barrier layer. An optional finishing layer may also be provided. The preferred alkaline structure is comprised of a core of a blend of a spheronizing/disintegrating agent such as microcrystalline cellulose and an alkaline material such as magnesium trisilicate or trisodium phosphate, although buffers or salts having the pH range of properties described above may be used.

The alkaline core structure is of high integrity and can withstand pressure of attrition during rotor layering operation and subsequent application of an

aqueous suspension of omeprazole. The drug layered alkaline core structure is coated with a non-enteric moisture barrier, and then coated with a pH-dependent, enteric membrane, insoluble in simulated gastric fluid but dissolving immediately in intestinal fluid thereby releasing omeprazole by disintegration in the proximal segment of the gastrointestinal tract in a pulsatile manner.

BRIEF DESCRIPTION OF THE DRAWINGS

A better understanding of the present invention as well as other objects and advantages thereof will become apparent upon consideration of the detailed disclosure thereof, when taken with the accompanying drawings, wherein

Figure 1 is the dissolution profile of a delayed delivery system for omeprazole at pH 5.2;

Figure 2 is the dissolution profile of a delayed delivery system for omeprazole at pH 6.0; and

Figure 3 is the dissolution profile of a delayed delivery system for omeprazole at pH 7.2.

Figure 4 is a representation of a tablet dose unit within the scope of the present invention.

Figure 5 is the drug release profile for a Multi-Compartment enteric delayed release system of the present invention with the omeprazole, using trisodium phosphite as the alkaline component.

DETAILED DESCRIPTION OF THE INVENTION

The delayed release drug delivery system of the present invention containing omeprazole is comprised of an alkaline core structure; layered omeprazole dispersion in aqueous dispersion of water soluble binder, such as hydroxypropylmethyl cellulose, other cellulose esters, water soluble polymers and the like; a separation barrier, which may be a non-enteric moisture barrier; and a delayed release enteric barrier providing gastro-resistant behavior to deliver omeprazole in the proximal segment (pH 5-6) of the gastrointestinal tract.

Microcrystalline cellulose is the preferred binder as it assists in the absorption of water, which is used to create an alkaline micro-environment for

each nonpareil central core by providing a hydroxyl ion concentration gradient. Once contact with water is made, there is migration of hydroxyl ions seeking a lower pH, moving toward omeprazole particles to enhance dissolution and to stabilize the omeprazole during dissolution in the acidic medium. A barrier of low water-solubility polymer or resin, such as ethylcellulose, cellulose acetate, or zein is provided to protect omeprazole-layered particles from subsequent delayed release membrane coats containing carboxylic functionalities during the coating operation.

I. Alkaline Core Structure

Basic alkaline material is selected from the group consisting of salts of strong basic cations and weak acidic anions such as Mg^{2+} , Ca^{2+} , or Al^{3+} and CO_3^{2-} , OH^- , and metal oxides including MgO , CaO , and Al_2O_3 , at a preferred pH of 9 or greater; organic buffers including Tris (hydroxymethyl) amino methane; and natural clays including montmorillonite and pharmaceutical necessities including sodium glycerophosphate (pH 9.5) and sodium borate (pH 9.5), ratio of omeprazole to alkaline material being from 1:1 to 1:5, preferably 1:1.5 – 1:2.5.

The alkaline core structure, in association with a spheronizing/disintegrating agent, is prepared by rotor layering nonpareils (e.g., 30/35 or 25/30 mesh, usually between 20 and 50 mesh) with a powder blend of water softenable polymer such as microcrystalline cellulose and an alkaline agent such as trisodium phosphate or magnesium trisilicate powder. A dispersion of hydroxypropyl cellulose is preferably used as a polymeric binding agent for depositing powder blend on the nonpareils. The powder blend and the binding agent are applied at appropriate powder feed rate, spray rate, air volume, and inlet temperature. Ratio of spheronizing/disintegrating agent is from 2:1 to 1:2, preferably 1:1.5 to 1.5:1.

II. Layered Drug Deposit

The layered omeprazole macroparticulates may be obtained by layering micronized omeprazole dispersion in an aqueous dispersion of water soluble/dispersible organic polymeric binders, especially cellulose-based polymers such as hydroxypropyl methylcellulose (traded as Opadry™

Y-5-7095, a registered trademark of Colorcon) or polysiloxane polymers such as Simethicone Emulsion 30% USP on the alkaline deposit cores using rotor layering equipment.

III. Separation Barrier

5 The separation barrier is then created over the layered drug deposit. After the drug layering operation, the layer may be formed by any commercial process, such as for example, layering over the drug layer a dispersion of trisodium phosphate and Opadry White YS 22-7719, or a semipermeable barrier composed of water soluble or water dispersible polymers (such as cellulose-
10 based polymers, such as cellulose esters, acetates, other derivatives and copolymers), ethylcellulose (e.g., Surelease®, Colorcon), cellulose acetate or zein.

Application of trisodium phosphate (or other pharmaceutically acceptable buffer with a pH greater than 9.0, etc. (as described below) as a separation
15 barrier may be accomplished by any commercially available process such as suspension layering, powder layering, or compression molding the trisodium phosphate (or other buffer) with a water-soluble binder (e.g., lactose or other pharmaceutically acceptable binder, including other sugars or carbohydrates), preferably when both materials are micronized, or dissolving the buffer, e.g., the
20 trisodium phosphate with a cosolvent (e.g., Carbowax® 3350 or 8000).

The barrier thus created inhibits the interaction between dissolved omeprazole (or other acid sensitive drug or biologically active material) and carboxylate ions provided by the delayed release pH enteric barrier. Inhibition of such interaction provides protection to omeprazole from degradation and
25 discoloration.

IV. Delayed Release Enteric Barrier

The delayed release enteric barrier is applied on the non-enteric barrier-coated material by any convenient commercial coating or layering process such as rotor-layering or fluidized bed coating, using an aqueous dispersion of
30 the enteric coating composition, such as, for example, 30% w/w of copolymers of methacrylic acid and ethyl acrylate, plasticized with a nontoxic,

pharmaceutically acceptable plasticizer, such as organic plasticizers, and especially triethyl citrate. An antiadherent, such as talc, is used to prevent agglomeration of the membrane-coated beads. As enteric coating materials, cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP-50), polyvinyl acetate phthalate (PVAP), co-polymerized acrylic polymers such as acrylic acid or methacrylic acid/methacrylic acid methyl esters (L30D-55), or similar compounds may be used, preferably HPMCP-50 and L30D-55.

The enteric coating layer also contains pharmaceutically acceptable plasticizers, such as water-soluble triacetin, triethyl citrate, or propylene glycol. The ratio of polymer to plasticizer may be, for example, between 10:1 to 6:1, preferably being 9:1 to 7:3, and more preferably 8.5:2 to 7.5:2; enteric polymers as selected, based on minimal lag time, followed by pulsatile kinetics; and minimal reactive carboxyl groups. Therefore, the organic-based enteric polymer, HPMCP-50 and water-based enteric polymer, L30D-55, are preferred, with an apparent pKa close to 4.3 (e.g., between 4.1 and 4.5). Insofar as the reactivity of carboxyl groups is concerned, all of these enteric materials produce degradation compounds which impart a tint of purple to the omeprazole-layered alkaline core structure. Therefore, in the present invention, a semipermeable barrier is intentionally applied between the omeprazole layer and the enteric membrane, in order to prevent the degradation of omeprazole.

V. Dissolution Profiles

Figure 1 represents the dissolution profile of a delayed delivery system for omeprazole at pH 5.2, and distinguishes between enteric membranes with regard to lag time and kinetics of drug release. As is evident from Figure 1, only CAT (cellulose acetate trimellitate) provides an acceptable, pulsatile release kinetics. However, CAT is not acceptable in this instance. Whereas pH 5.2 is acceptable for the fasted, but not for the non-fasted stated, CAT would deliver the drug in the non-fasted stomach where the pH can approach 4-5 in some cases.

Figure 2 represents the dissolution profile of a delayed delivery system for omeprazole at pH 6.0, representative of the non-fasted state in the proximal segment of the small intestine. As indicated, HPMCP and L30D-55 provide an optimum pulsatile release profile at pH 6.0. CAT, on the other hand, while
5 providing an optimum pulsatile release profile at pH 6.0, is not acceptable; because of its low pKa, CAT would deliver the drug in the non-fasted stomach. The other materials, CAP and CAS, do not exhibit satisfactory pulsatile release profiles and, in fact, the profiles tend to become sigmoidal in shape.

Figure 3 represents the dissolution profile of a delayed delivery system
10 for omeprazole at pH 7.2. As shown, all enteric barrier materials provide acceptable pulsatile release kinetics; however, a pH of 7.2 approaches that of the large intestine, which is 7.5 to 8.0. Material having a higher pH, 7.2, will not deliver the drug in the proximal segment of the small intestine, where the pH ranges from 4.7 to 6.5. HPMCP and L30D-55 provide most appropriate
15 materials for optimum pulsatile release in the targeted area.

Figure 4 shows one example of a multicompartment, enteric delayed release system dose unit of the present invention 2 comprising a substrate 4 having alternating subseparation layers 6, 8, 10 and 11, and drug layers 12, 14, 16 and 18. A separation layer 20 overlays all of the previous layers and is in turn
20 covered with an enteric membrane 22 and a finish coat 24.

Figure 5 shows a drug release profile of a multicompartment, enteric delayed release system like that of Figure 4. As can be seen from the graph, the initial release of the omeprazole was delayed for approximately two hours, with a rapid and steady release occurring quickly over an approximately ten minute
25 period.

EXAMPLES

The specific nature of the composition of the present invention will be more fully apparent from consideration of the following specific examples of preferred embodiments thereof. In the examples, as in the preceding description,
30 all parts and percentages are given by weight unless otherwise indicated.

Example 1Preparation of Alkaline Core Structure

	Nonpareils 30/35 mesh	750 g.
	Magnesium Trisilicate	1500 g.
5	Microcrystalline Cellulose	1500 g.
	Klucel (6% w/w/ = 4175)	250.5g.

Total: 4000.5g.

- 10 The preparation of the alkaline core is achieved by using a blend of a
spheronizing agent such as microcrystalline cellulose and an alkaline material
such as magnesium trisilicate (preferably, in a 50/50 ratio) which is powder-
layered on 30/35 mesh non-pareils, using a 12" insert in a fluid bed granulator
dryer (traded as FLM-15 EX by Vector, Corporation, Marion, Ia.). Particle size
15 analysis is as follows:

Mesh	14	16	18	20	25	30	Pan
Percent Retained	2	22	64	10	1	1	4

- 20 The process yield was 90%. The theoretical potency of magnesium trisilicate is
375%.

Example 2Composition of Suspension for Layered Drug Deposit

25	Omeprazole	111 g.
	Opadry Y-5-7095	44.4g.
	Water, deionized	954.6g.
	Total:	1110g.

30

Example 3

Composition of Layered Drug Deposit

	<u>Solids, g.</u>	<u>%, w/w</u>
Omeprazole	111	9.607
Opadry Y-5-7095	44.4	3.843
5 Alkaline Core Structure	1000.0	86.550
	<hr/>	<hr/>
	1155.4	100.000

The omeprazole layer dispersion is prepared by weighing purified water into a
10 tared container equipped with a Lightnin Mixer with impeller. With vigorous
mixing, hydroxypropyl methylcellulose (Opadry Y-5-7095) is dispersed in water
to prepare a smooth paste. Then, remaining water is added to prepare a clear
dispersion. To this dispersion, omeprazole (111 g.) is added, to obtain a final
omeprazole concentration of 10% w/w. The omeprazole suspension is
15 suspension-layered on magnesium trisilicate pellets, using a 12" rotor insert in a
fluid bed granulator dryer (traded as FLM-15 EX by Vector Corporation, Inc.).

Example 4Preparation of Non-Enteric Moisture Barrier

20 To the drug deposit core, a 3% weight gain is applied, using a water-based
dispersion of ethylcellulose (traded as Surelease^R by Colorcon, Inc., Pa.). this is
accomplished by using a 12" rotor insert in the FLM-15 EX fluid bed granulator
dryer.

Example 5Delayed Release Enteric Barrier(s)

	Eudragit L30D-55	594.3 g.
	Talc, U.S.P.	35.66 g.
5	Triethyl Citrate	35.66 g.
	Water, Deionized	334.33 g.
	<hr/>	
	Total:	1,000.00 g.

- 10 A water-based dispersion of Eudragit L30D-55, plasticized with triethyl citrate is applied to provide a weight gain of 15%. An antiadherent talc is used to prevent agglomeration of the membrane-coated beads.

	Cellulose Acetate Phthalate	100 g.
15	Diethyl Phthalate	25.08 g.
	Water, Deionized	26.25 g.
	Acetone, N.F.	848.75 g.
	<hr/>	
	Total:	1000.00 g.

20

An organic-based dispersion of cellulose acetate phthalate, plasticized with diethyl phthalate, is applied to provide a weight gain of 15%

	Cellulose acetate trimellitate, N.F.	100.08 g.
	Triacetin	25.08 g.
25	Water, Deionized	26.25 g.
	Acetone, N.F.	848.75 g.
	Total:	1000.00 g

- 30 An organic-based dispersion of cellulose acetate trimellitate, plasticized with triacetin, is applied to provide a weight gain of 15%.

12

	Hydroxypropyl methylcellulose phthalate (HPMCP-50)	100.0 g.
5	Acetylated monoglyceride (Myvacet 9-45)	15.0 g.
	Water, Deionized	44.25 g.
10	Acetone, N.F.	840.75 g.
		<hr/>
		1000.00 g.

- 15 An organic-based dispersion of HPMCP-50, plasticized with Myvacet 9-45, is applied to provide a weight gain of 15%. A supercoat of 2% weight gain, using Poadry 7065 (10% w/w dispersion) is used to finish off the coating operation. The potency of omeprazole in imeprazole beads will be as follows:

20

Example 6Potencies at Various Stages Coating, Percent

	Drug layered drug deposit	= 9.607
25	Sub-coated drug layered beads (2% weight gain based on alkaline core structure)	= 9.444
	Semipermeable barrier coat (1% weight gain)	= 9.364
30	Enteric-coated drug layered beads (15% weight gain)	= 8.312

13

Super-coated Enteric-coated
drug-layered beads
(2% weight gain) = 8.189

5 For 20 mg. dosage, therefore, 244 mg. of pellets are required.

Example 7

Composition of alkaline core structure

	Nonpareils 25/30 mesh	750.0 g
10	Trisodium Phosphate (1.5% w/w)	31.68 g
	Opadry White YS-22-7719 (16.39% w/w)	21.32 g
	TOTAL:	803.00 g

The preparation of the separation layer is achieved by suspension layering on
15 25/30 mesh nonpareil seeds a dispersion of trisodium phosphate and Opadry
White YS-22-7719 in purified water, using a twelve inch insert in a fluidized bed
granulator dryer (FLM-15-ES by Vector Corp., Marion, Ia). The total quantity
to be applied for five separation layers is 1289.4 grams.

20 Example 8

Composition of drug layer

	Omeprazole USP, micronized	165.0 g
	Lactose monohydrate fine powder	562.9 g
	Talc, USP	29.6 g

25 The powdered drug layer consists of 165.0 grams of micronized Omeprazole
USP and 592.5 grams Lactose monohydrate fine powder (micronized) and 29.6
grams of talc. The particle size of omeprazole and the excipients is below 20
microns. The theoretical quantity to be applied to the multilayered separation
30 layered pellets is 757.5 grams.

Example 9

Theoretical quantity to be applied to the individual separation and rug layers as a total weight of a batch preparation.

	Sublayer 1 To substrate	214.9 g
5	Drug layer 1 To separation layered pellets	189.4 g
	Sublayer 2 To drug layered pellets	214.9 g
	Drug layer 2 to separation layered pellets	189.4 g
	Sublayer 3 to drug layered pellets	214.9 g
	Drug layer 3 To separation layered pellet	189.4
10	Sublayer 4 to drug layered pellets	214.9 g
	Drug layer 4 To separation layered pellet	189.4
	Sublayer 5 to drug layered pellets	429.8 g

The total theoretical to be applied to the five separation layers and the four drug layers comprises 1289.4 grams and 757.6 grams, respectively.

Example 10

Composition of alkaline core structure

	Nonpareils 25/30 mesh	750.0 g
20	Trisodium Phosphate (1.06% w/w)	5.28 g
	Opadry White YS-22-7719 (16.38% w/w)	35.22 g
	TOTAL:	790.5 g

The preparation of the separation layer is achieved by suspension layering on 25/30 mesh nonpareil seeds a dispersion of trisodium phosphate and Opadry White YS-22-7719 in purified water, using a twelve inch insert in a fluidized bed granulator dryer (FLM-15-ES by Vector Corp., Marion, Ia). The total quantity to be applied for the alkaline core structure is 214.9 grams.

Example 11

Composition of drug layer

	Omeprazole USP,	135.35 g
	Opadry Y-5-7095	133.35 g
5	Simethicone Emulsion 30%, USP	0.606 g
	Total	267.306 g

The suspension of the layered drug deposit is composed of micronized drug particles in a dispersion of Simethicone emulsion 30% USP and Opadry White Y-5-7095 in purified water. Total theoretical quantity to be applied to the four
10 drug layers is 1333.5 grams. The Omeprazole suspension is suspension layered on the alkaline core structure (composed of water-soluble trisodium phosphate), using a twelve inch rotor insert in a fluid bed granulation dryer (FLM-15 ES, Vector Corporation, Marion, Ia).

15

While the invention has been described in connection with an exemplary embodiment thereof, it will be understood that many modifications will be apparent to those of ordinary skill in the art, and that this application is intended to cover any adaptations of variations thereof. Therefore, it is manifestly
20 intended that this invention be only limited by the claims and the equivalents thereof.

WHAT IS CLAIMED IS:

1. A drug delivery system for which comprises a plurality of pellets, each of said pellets comprising a core of a basic alkaline material, a coating of
5 omeprazole surrounding said core of alkaline material; and an enteric membrane, said system being characterized by having multiple layers of omeprazole separated by non-enteric moisture barriers surrounding omeprazole layers and at least one enteric layer comprising enteric film former plasticized with a water soluble plasticizer, said enteric membranes
10 having a weight gain sufficient to permit release of omeprazole after immersion in both 0.1N HCl for two hours for enteric behavior, followed by pH 6.8 buffer, said release corresponding to a drug release pattern of 0% of the total omeprazole released after at least 1.5 hours of measurement in 0.1N HCl and from 60-80% of the total omeprazole released after 45 minutes of measurement
15 in said pH 6.8 buffer.
2. The drug release system of claim 1 wherein said core comprises both a basic alkaline material and a spheronizing structuring agent.
- 20 3. The drug release system of claims 1 and 2 wherein each of said pellets comprise said core and at least three distinct drug layers comprising omeprazole, each of said drug layers being separated from other drug layers by sub-separation layers comprising moisture barrier layers.
- 25 4. The drug release system of claims 1 and 2 wherein each of said pellets comprise said core and at least three distinct drug layers comprising omeprazole, each of said drug layers being separated from other drug layers by sub-separation layers comprising moisture barrier layers, and wherein said moisture barrier layers comprise non-enteric moisture barrier comprising water-insoluble
30 semipermeable polymeric membranes.

5. The drug release system of claim 4 wherein said non-enteric moisture barrier layer comprises a cellulose-based resin.
6. The drug release system of claim 3 wherein said at least one enteric layer comprising enteric film former plasticized with a water soluble plasticizer comprises a cellulose-based polymer.
7. The drug release system of claim 3 wherein said enteric coating comprises an acrylic resin.
8. The drug release system of claims 1 and 2 wherein each of said pellets comprise said core and at least three distinct drug layers comprising omeprazole, each of said drug layers being separated from other drug layers by sub-separation layers comprising moisture barrier layers, wherein said at least one enteric layer comprising enteric film former plasticized with a water soluble plasticizer comprises a cellulose-based polymer or acrylic resin, and said water-soluble plasticizer comprises a plasticizer selected from the group consisting of triacetin, triethyl citrate and propylene glycol..
9. A delayed release drug delivery system of omeprazole for site-specific delivery and pulsatile (bolus) kinetics, which comprises a plurality of pellets, each of said pellets having a core of a basic alkaline material and a spheronizing structuring agent; a multi-layer coating of
- a) at least one omeprazole layer surrounding said core of alkaline material;
 - b) a non-enteric moisture barrier surrounding said at least one omeprazole layer; and
 - c) at least one layer of an enteric membrane comprising enteric film former plasticized with a water soluble plasticizer, said enteric membrane having a weight gain sufficient to permit release of omeprazole in 0.1N HCl for at least 1.5 hours for enteric behavior, followed by pH 6.8 buffer, corresponding to a drug release pattern of 0%


of the total omeprazole released after two hours of measurement in 0.1N HCl and from 60-80% of the total omeprazole released after 45 minutes of measurement in said pH 6.8 buffer.

- 5 10. The delayed release drug delivery system as defined in Claim 9, wherein said basic alkaline material is selected from the group consisting of salts of strong basic cations and weak acidic anions; organic buffers, natural clays, and sodium borate, the ratio of omeprazole to alkaline material being from 1:1 to 1:5.
- 10 11. The delayed release drug delivery system as defined in Claim 9, wherein said non-enteric moisture barrier is selected from the group consisting of water-insoluble, semipermeable polymeric membranes of ethylcellulose, cellulose acetate, and zein, wherein said delayed release enteric barrier is selected from the group consisting of acrylic and resin lacquers and being anionic polymers of
- 15 methacrylic acid, methacrylic acid esters or cellulose phthalic acid ester derivatives, wherein said plasticizer is selected from the group consisting of water-soluble triethyl citrate, triacetin, and propylene glycol, ratio of polymer to plasticizer being 9:1 to 7:3, and wherein the ratio of alkaline material to spheronizing/disintegrating agent is 2:1 to 1:2 in said central alkaline core
- 20 structure.
12. The delayed release pellets of omeprazole which comprises a plurality of pellets, each of said pellets having a core of a basic alkaline material and a spheronizing structuring agent; a multi-layer coating of omeprazole surrounding
- 25 said core of alkaline material; a non-enteric moisture barrier surrounding said omeprazole layers; and multilayers of an enteric membrane comprising enteric film form plasticized with a water soluble plasticizer, weight gain of said enteric membranes being sufficient to permit release of omeprazole in 0.1N HCl for two hours for enteric behavior, followed by pH 6.8 buffer, corresponding to a drug
- 30 release pattern of 0% of the total omeprazole released after two hours of

measurement in 0.1N HCl and from 60-80% of the total omeprazole released after 45 minutes of measurement in said pH 6.8 buffer.


1/5

FIG. 1 DISSOLUTION PROFILE OF DELAYED DELIVERY SYSTEM
FOR OMEPRAZOLE AT pH 5.2
(With 30 Minutes Gastric Presoak)




2/5

FIG. 2 DISSOLUTION PROFILE OF DELAYED DELIVERY SYSTEM
FOR OMEPRAZOLE AT pH 6.0
(With 30 Minutes Gastric Presoak)



3/5

FIG. 3 DISSOLUTION PROFILE OF DELATED DELIVERY SYSTEM
FOR OMEPRAZOLE AT pH 7.2
(With 30 Minutes Gastric Presoak)



4/5




FIG. 4

5/5

DRUG RELEASE PROFILE
Multi-Compartment Enteric Delayed Release System
(Suspension Layering)




FIGURE 5

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/20851

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/50 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 01623 A (ASTRA AB ;BERGSTRAND PONTUS JOHN ARVID (SE); LOEVGREN KURT INGMAR) 25 January 1996 see page 7, line 19 - page 12, line 20 ---	1-12
Y	EP 0 496 437 A (HAESSLE AB) 29 July 1992 cited in the application see page 3, line 35 - page 5, line 20 see page 18; table 5 -----	1-12

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

20 February 1998

Date of mailing of the international search report

13.03.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seegert, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20851

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9601623 A	25-01-96	AU 2993795 A	09-02-96
		BR 9506018 A	02-09-97
		CA 2170647 A	25-01-96
		CN 1134666 A	30-10-96
		CZ 9600732 A	17-07-96
		DE 723436 T	11-09-97
		EP 0723436 A	31-07-96
		ES 2100142 T	16-06-97
		FI 961057 A	29-03-96
		HR 950349 A	30-06-97
		HU 75775 A	28-05-97
		JP 9502739 T	18-03-97
		NO 960950 A	07-03-96
		NZ 289948 A	27-07-97
		PL 313387 A	24-06-96
		SK 30196 A	10-09-97
		ZA 9505548 A	08-01-96

EP 0496437 A	29-07-92	GB 2189698 A	04-11-87
		SG 154294 G	17-03-95
		AR 240250 A	30-03-90
		AT 140387 T	15-08-96
		AU 601974 B	27-09-90
		AU 7191287 A	05-11-87
		CA 1292693 A	03-12-91
		CN 1020852 B	26-05-93
		CY 1810 A	20-10-95
		DE 3751860 D	22-08-96
		DE 3751860 T	21-11-96
		DE 3783394 A	18-02-93
		DK 215887 A	31-10-87
		EP 0247983 A	02-12-87
		EP 0567201 A	27-10-93
		ES 2006457 T	01-01-94
		ES 2091971 T	16-11-96
		HK 52897 A	02-05-97
		HK 135294 A	09-12-94
		HR 920854 A	31-10-94
		IE 61416 B	02-11-94
		JP 1863556 C	08-08-94

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/20851

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0496437 A		JP 62258320 A	10-11-87
		JP 5294831 A	09-11-93
		LT 1683 A,B	25-07-95
		LV 10357 A	20-02-95
		LV 10357 B	20-04-96
		NO 174239 B	27-12-93
		PH 25701 A	18-09-91
		SI 8710681 A	31-10-96
		SU 1820837 A	07-06-93
		US 4786505 A	22-11-88

THIS PAGE BLANK (USPTO)